EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis

Justin M Oldham, Megan L Neely, Daniel M Wojdyla, Mridu Gulati, Peide Li, Divya C Patel, Scott M Palmer, Jamie L Todd, IPF-PRO Registry Investigators

CHEST · 2025-08 · 168 (2) · 415-422

DOI: 10.1016/j.chest.2025.02.018 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2025-08. Verfasst von Justin M Oldham und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Lung. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Boehringer Ingelheim Pharma GmbH und Co. KG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with lung function decline and high mortality. RESEARCH QUESTION: What are the associations between thresholds of lung function decline and the risk of mortality in patients with IPF? STUDY DESIGN AND METHODS: The Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry enrolled patients with IPF that was diagnosed or confirmed at the enrolling center within the prior 6 months. Associations between time to first decline in FVC or diffusing capacity of the lungs for carbon monoxide (Dlco) of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted (and ≥ 15% predicted for Dlco) and risk of subsequent death or lung transplantation was assessed using Cox proportional hazards models with a time-dependent covariate. Models were unadjusted or adjusted for FVC and Dlco % predicted, age, sex, smoking status, BMI, antifibrotic treatment (yes or no), and oxygen use at enrollment. RESULTS: Among 1,001 patients, median follow-up time was 38.4 months. Significant associations were observed between all thresholds of decline in FVC and Dlco % predicted and the risk of death or lung transplantation in unadjusted and adjusted analyses. In adjusted analyses, absolute declines in FVC of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted were associated with 1.8-fold, 2.3-fold, and 2.7-fold increases in the risk of subsequent death or lung transplantation, whereas absolute declines in Dlco of ≥ 2% predicted, ≥ 5% predicted, ≥ 10% predicted, and ≥ 15% predicted were associated with 2.0-fold, 1.4-fold, 1.5-fold, and 1.9-fold increases in the risk of subsequent death or lung transplantation, respectively. For Dlco, but not FVC, the increase in risk generally was greater for patients meeting a threshold based on a relative rather than an absolute decline. INTERPRETATION: Our results show that even small declines in FVC and Dlco % predicted inform prognosis in patients with IPF. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01915511; URL: www. CLINICALTRIALS: gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisLungAgedFemaleHumansMaleMiddle AgedDisease ProgressionLung TransplantationPrognosisProportional Hazards ModelsProspective StudiesPulmonary Diffusing CapacityRegistriesRespiratory Function TestsRisk FactorsVital Capacity

Stichwörter der Autor:innen

interstitial lung diseasepulmonary fibrosisrespiratory function tests

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI.
  • Duke Clinical Research Institute, Durham, NC; Duke University Medical Center, Durham, NC.
  • Duke Clinical Research Institute, Durham, NC.
  • Yale School of Medicine, New Haven, CT.
  • Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
  • Duke Clinical Research Institute, Durham, NC; Duke University Medical Center, Durham, NC. Electronic address: jamie.todd@duke.edu.

Förderung

  • Boehringer Ingelheim
  • Boehringer Ingelheim Pharma GmbH und Co. KG

Zitieren

APA

Oldham, J. M., Neely, M. L., Wojdyla, D. M., Gulati, M., Li, P., Patel, D. C., Palmer, S. M., Todd, J. L., & IPF-PRO Registry Investigators (2025). Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. CHEST, 168(2), 415-422. https://doi.org/10.1016/j.chest.2025.02.018

Vancouver

Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, et al. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. CHEST. 2025;168(2):415-422. doi:10.1016/j.chest.2025.02.018

BibTeX
@article{Oldham2025,
  author = {Oldham, Justin M and Neely, Megan L and Wojdyla, Daniel M and Gulati, Mridu and Li, Peide and Patel, Divya C and Palmer, Scott M and Todd, Jamie L and IPF-PRO Registry Investigators, IPF-PRO Registry Investigators},
  title = {Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis},
  journal = {CHEST},
  year = {2025},
  volume = {168},
  number = {2},
  pages = {415--422},
  doi = {10.1016/j.chest.2025.02.018}
}
Kostenlos starten →